20/20 Biolabs, Inc.

20/20 Biolabs, Inc. (AIDX) has filed a Definitive Proxy Statement (DEF 14A) announcing a Special Meeting of Stockholders on December 9, 2026. The primary purpose of the meeting is to vote on a proposal to authorize the board of directors to implement one or more reverse stock splits of the Company's outstanding common stock, with ratios ranging from 1-for-2 to 1-for-250, at any time prior to December 31, 2028. This action is primarily intended to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share, with a compliance deadline of January 13, 2027. A second proposal seeks authorization to adjourn the meeting if necessary to solicit additional proxies. The filing also details current share ownership among management and major shareholders.

20/20 Biolabs, Inc. announced preliminary Q2 2026 results, marking its best quarterly cancer testing revenue to date, with strong year-over-year growth anticipated for Q3 and Q4. The company secured 29 new accounts and was selected for the Vermont Firefighter Cancer Screening Program. Additionally, 20/20 Biolabs launched a pilot program with Giant Food for its OneTest for Longevity and highlighted the recent passage of the Multi-Cancer Early Detection Screening Coverage Act, which could enable Medicare reimbursement by 2028.

20/20 BioLabs announced an investor webinar on August 5, 2026, where CEO Jonathan Cohen will discuss the company's recent East Asia business development tour. The discussion will cover participation in BIO Asia-Taiwan, strategic meetings in Taipei, Tokyo, and Seoul, and the company's East Asia roll-up strategy, including potential mergers, acquisitions, licensing, and partnerships. Management believes East Asia is a crucial market for protein biomarker-based cancer screening and aims to leverage regional relationships to support its technology platform and achieve Medicare reimbursement for multi-cancer early detection by 2028.

20/20 BioLabs announced its management team met with potential acquisition, licensing, joint venture, and commercial partners in Taipei, Tokyo, and Seoul as part of its East Asia roll-up strategy. The company is evaluating opportunities to expand its mission of early detection and prevention of cancers and chronic diseases. This initiative aims to strengthen its technology platform, expand data resources, and accelerate commercialization in a region with established healthcare ecosystems for protein biomarker-based cancer screening and health-check programs.

20/20 BioLabs, Inc. announced a standstill agreement with Streeterville Capital, LLC, effective July 16, 2026. This agreement temporarily restricts Streeterville from converting its Series E Convertible Preferred Stock into common stock for 120 days, unless the common stock trades at least 10% above the Nasdaq Minimum Price. The purpose of this agreement is to mitigate potential near-term dilution while preserving existing rights and obligations.

20/20 Biolabs, Inc. received a notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price rule, having traded below this threshold for 30 consecutive business days. The company has been granted a 180-day period, until January 13, 2027, to regain compliance. Additionally, the company entered into a 120-day standstill agreement with Streeterville Capital, LLC, preventing the conversion of Series E preferred stock into common stock unless the common stock trades at least 10% greater than the Nasdaq Minimum Price.

20/20 BioLabs outlined its strategy to position OneTest™ for Cancer as an affordable, multi-cancer early detection blood test, aiming for potential Medicare reimbursement under a new statutory pathway beginning in 2028. The company highlighted its differentiated approach using protein tumor markers and serial testing, and provided preliminary estimates for its second-quarter MCED revenue, expecting it to be its highest to date and at least 30% higher than the prior-year period. However, the company emphasized that FDA authorization and CMS determination of clinical appropriateness are required and not yet obtained.

20/20 Biolabs presented an investor webinar detailing its OneTest multi-cancer early detection strategy. The presentation highlighted the recent passage of the Multi-Cancer Early Detection Screening Coverage Act, which creates a Medicare reimbursement pathway for such tests by 2028. 20/20 Biolabs believes its OneTest, utilizing biomarker tracking, machine learning, and anti-inflammatory diet integration, is well-positioned for FDA authorization and CMS coverage. The company also outlined its M&A strategy and projected significant revenue growth post-Medicare reimbursement, drawing parallels to Cologuard's success.

20/20 Biolabs, Inc. announced its 2026 Annual Meeting of Stockholders to be held virtually on August 18, 2026. Key proposals include increasing the authorized common stock from 50 million to 500 million shares to provide flexibility for future issuances, and the approval of a new 2026 Equity Incentive Plan. Stockholders will also vote on the election of six director nominees and the ratification of the company's independent auditor.

20/20 Biolabs, Inc. announced the launch of a recurring monthly investor webinar series to enhance communication and transparency with shareholders and the investment community. The first webinar is set for July 1, 2026, at 12:00 p.m. ET, and subsequent sessions will occur on the first Wednesday of each month. The company also plans to offer a promotional discount code for its OneTest product to all webinar attendees.